MetaVia (MTVA) risk factors, FY2024 10-K

Risks related to our financial position and need for capital

1. 01As we do no generate any revenue, we are dependent on working capital to fund our business plan, and raising additional capital may cause dilution to existing stockholders, restrict our operations or require us to relinquish rights to our technologies
2. 02Future sales, or the perception of future sales, by us or our securityholders could cause the market price of our common stock to decline
3. 03Adverse global economic conditions could have a material adverse effect on our business, results of operations and financial condition and liquidity
4. 04Conditions in the banking system and financial markets, including the failure of banks and financial institutions, could have an adverse effect on our operations and financial results
5. 05We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success
6. 06Public opinion and scrutiny of treatments for obesity and overweight patients may impact public perception of our Company and DA-1726, or may adversely affect our ability to conduct our business and our business plans
7. 07We may be required to make significant payments under the 2022 License Agreement
8. 08Even if we obtain favorable clinical results, we may not be able to obtain regulatory approval for, or successfully commercialize DA-1241 and DA-1726
9. 09have not obtained regulatory approval for any product candidate, and it is possible that DA-1241 and DA-1726 will never obtain regulatory approval
10. 10Preliminary, interim and topline data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data
11. 11Results of earlier clinical trials may not be predictive of the results of later-stage clinical trials
12. 12Product candidates may cause undesirable side effects that could delay or prevent their marketing approval, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any, including marketing withdrawal
13. 13Our efforts to discover drug candidates beyond our current drug candidates may not succeed, and any drug candidates we recommend for clinical development may not actually begin clinical trials
14. 14Delays in our clinical trials may lead to a delay in the submission of marketing approval applications and jeopardize our ability to potentially receive approvals and generate revenues from the sale of our products
15. 15We may develop DA-1241 and DA-1726, and potentially future product candidates, in combination with other therapies, which exposes us to additional risks
16. 16Any collaboration arrangement that we may enter into in the future may not be successful, which could adversely affect our ability to develop and commercialize our current and potential future drug candidates
17. 17We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do
18. 18patients sometimes undergo a gastric bypass procedure, with salutary effects on the many co-morbid conditions of obesity
19. 19Our commercial success depends upon attaining significant market acceptance of our product candidates, if approved, among hospitals, physicians, patients and healthcare payors
20. 20Even if we are able to commercialize a future pharmaceutical drug candidate, the profitability of such product candidate will likely depend in significant part on third-party reimbursement practices, which, if unfavorable, would harm our business
21. 21We may engage in strategic transactions that could impact on our liquidity, increase our expenses and present significant distractions to our management
22. 22Product liability lawsuits against us could cause us to incur substantial liabilities and could limit commercialization of any product candidate that we may develop
23. 23If we or our third-party manufacturers fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have an adverse effect on the success of our business
24. 24We rely and will continue to rely on collaborative partners regarding the development of our research programs and product candidates
25. 25If, in the future, we are unable to establish sales and marketing capabilities or to selectively enter into agreements with third parties to sell and market our product candidates, we may not be successful in commercializing our product candidates if and when they are approved
26. 26Any product candidate for which we obtain marketing approval could be subject to marketing restrictions or withdrawal from the market, and we may be subject to penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our products
27. 27We or any potential collaborator may never receive regulatory approval to market our product candidates outside of the U.S
28. 28Current and future legislation may increase the difficulty and cost of obtaining marketing approval and commercialization of our product candidates and affect the prices we may obtain
29. 29Governments outside the U.S. tend to impose strict price controls, which may adversely affect our revenues, if any
30. 30Our ability to use our NOLs to offset future taxable income may be subject to certain limitations
31. 31Tax matters, including the changes in corporate tax rates, disagreements with taxing authorities and imposition of new taxes could impact the results of our operations and financial condition
32. 32the Tax Act and any future tax reform is uncertain and our business and financial condition could be adversely affected. The impact of the Tax Act and any future tax reform on holders of our common stock is likewise uncertain and could be adverse
33. 33Federal legislation and actions by state and local governments may permit reimportation of drugs from foreign countries into the U.S., including foreign countries where the drugs are sold at lower prices than in the U.S., which could adversely affect our operating results

Risks related to dependence on third parties

1. 34unreliable, and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications
2. 35We rely on third parties to manufacture our product candidates and preclinical and clinical drug supplies
3. 36We may engage in future acquisitions, mergers or in-licenses and out-licenses of technology that could disrupt our business, cause dilution to the organization’s stockholders and harm our financial condition and operating results
4. 37We may form or seek strategic alliances or enter into additional licensing arrangements in the future, and we may not realize the benefits of such alliances or licensing arrangements
5. 38Our employees, principal investigators, CROs and consultants may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have a material adverse effect on our business

Risks related to intellectual property

1. 39If we are unable to obtain and maintain sufficient intellectual property rights, our competitive position could be harmed
2. 40We may not be able to protect or practice our intellectual property rights throughout the world
3. 41We may become involved in lawsuits to protect or enforce our intellectual property, which could be expensive, time-consuming and unsuccessful
4. 42Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business
5. 43Intellectual property litigation could cause us to spend substantial resources and distract our personnel from their normal responsibilities
6. 44We may be subject to damages resulting from claims that our employees or we have wrongfully used or disclosed alleged trade secrets of their former employers
7. 45Our trade secrets are difficult to protect and if we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed
8. 46Our ability to obtain and maintain our patent protection depends on compliance with various procedural, documentary, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements
9. 47Intellectual property rights do not necessarily address all potential threats to our competitive advantage

Risks related to operations, employee matters and managing growth

1. 48We currently have a small number of employees and consultants, and our future success depends on our ability to retain our executive officers and to attract, retain and motivate qualified personnel
2. 49We may need to increase the size of our organization, and we may experience difficulties in managing this growth
3. 50We intend to market our product candidates outside of the U.S., and if we do, we will be subject to the risks of doing business outside of the U.S
4. 51The pharmaceutical industry is highly competitive and is subject to rapid and significant technological change, which could render our technologies and products obsolete or uncompetitive

Risks related to our common stock

1. 52The price of our common stock may be volatile and fluctuate substantially, which could result in substantial losses for holders of our common stock
2. 53As of December 31, 2024, our largest stockholder, Dong-A beneficially owned approximately 62% of our voting rights. As a result, Dong-A is able to exert a significant influence on the outcome of corporate actions requiring stockholder approval, including mergers, share capital increases and other extraordinary items
3. 54Provisions in our corporate charter documents and under Delaware law may make an acquisition of MetaVia, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management
4. 55We may fail to comply with the continued listing requirements of Nasdaq, such that our common stock may be delisted and the price of our common stock and our ability to access the capital markets could be negatively impacted
5. 56We are a “smaller reporting company” and we cannot be certain if the reduced reporting requirements applicable to such companies could make our common stock less attractive to investors
6. 57We have identified material weaknesses in our internal control over financial reporting that could, if not remediated, result in material misstatements in our financial statements or impair our ability to produce accurate and timely consolidated financial statements
7. 58Our business and operations may suffer in the event of system failures or other unplanned events
8. 59or inappropriate disclosure of confidential or proprietary information, we could incur liability, and the further development and commercialization of our product candidates could be delayed
9. 60An active trading market for our common stock may not be maintained
10. 61If securities analysts do not publish research or reports about our business or if they publish negative evaluations of our business, the price of our stock could decline
11. 62We incur increased costs as a result of operating as a public company and our management is required to devote substantial time to compliance initiatives
12. 63We do not anticipate declaring or paying, in the foreseeable future, any cash dividends and, consequently, the ability of our stockholders to achieve a return on their investment will depend on appreciation in the price of our common stock